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A B S T R A C T
The specific targeting of diseases, particularly cancer, is a primary aim in drug development, as
specificity reduces unwelcome effects on healthy tissue and increases drug efficacy at the target
site. Drug specificity can be increased by improving the delivery system or by selecting drugs with
affinity for a molecular ligand specific to the disease state. The role of the prosurvival Bcl-2 protein
in maintaining the normal balance between apoptosis and cellular survival has been recognized for
more than a decade. Bcl-2 is vital during development, much less so in adults. It has also been
noted that some cancers evade apoptosis and obtain a survival advantage through aberrant
expression of Bcl-2. The new and remarkably diverse class of drugs, small-molecule inhibitors of
Bcl-2 (molecular weight approximately 400 to 800 Daltons), is examined herein. We present the
activities of these compounds along with clinical observations, where available. The effects of
Bcl-2 inhibition on attenuation of tumor cell growth are discussed, as are studies revealing the
potential for Bcl-2 inhibitors as antiangiogenic agents. Despite an enormous body of work
published for the Bcl-2 family of proteins, we are still learning exactly how this group of molecules
interacts and indeed what they do. The small-molecule inhibitors of Bcl-2, in addition to their
therapeutic potential, are proving to be an important investigative tool for understanding the
function of Bcl-2.
J Clin Oncol 26:4180-4188. © 2008 by American Society of Clinical Oncology
INTRODUCTION
Evolution has adapted us more poorly to fight
cancer compared with almost any other disease,
and until recent years, approaches to treatment of
cancer had changed little. Physical removal of the
tumor by surgery remains an important first-line
treatment but lacks effectiveness in the face of
highly aggressive or invasive cancers, cancers that
are difficult to detect, or those that have reached a
metastatic stage. Radiotherapy and chemotherapy
are the conventional second-line treatments;
however, both are nonspecific to the tumor tissue.
They are generally toxic to healthy tissue and, nota-
bly for DNA-directed drugs such as cisplatin (cis-
diamminedichloroplatinum), may ultimately be
carcinogenic in their own right.1,2
This review deals with a novel class of tar-
geted drugs developed by several independent
groups over the last few years: small-molecule
inhibitors of the antiapoptotic protein Bcl-2 (B-cell
lymphoma/leukemia-2). The antitumor and anti-
angiogenic potential of these compounds will be
discussed. In the literature, the term Bcl-2 inhibitor
encompasses various drugs that bind the antiapop-
totic Bcl-2 family members with more or less effi-
cacy. None of the compounds here discussed are
specific to only one member of the Bcl-2 family.
BCL-2–RELATED PROTEIN FAMILY
Bcl-2 is a 26-kDa protein localized to the mitochon-
dria and endoplasmic reticulum that acts as a key
inhibitor of apoptosis. Expression of Bcl-2 is essen-
tial for growth of certain tumor cell lines in vitro and
has been found upregulated in a variety of tumor
types in vivo.3-5 The interactions of other Bcl-2 fam-
ily members and their role in modulating Bcl-2
functions have been reviewed,6,7 and a detailed dis-
cussion of such is beyond the scope of this review. A
brief description here may aid the appreciation of
drug actions. Bcl-2 and other members of the family
are primary regulators of apoptosis (Fig 1). They
maintain a balance within the cell that is biased to-
ward survival. Bcl-2 structure consists of five do-
mains, Bcl-2 homology (BH) domains 1 to 4 plus a
transmembrane domain (Fig 2). The other Bcl-2
family members bear four or fewer of these domains
and display varying degrees of homology (Fig 2).
The BH1-3 domains can form a labile hydrophobic
groove, on tertiary folding, that allows binding of
other molecules via their own BH3 domain. This
JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E
VOLUME 26  NUMBER 25  SEPTEMBER 1 2008
4180 © 2008 by American Society of Clinical Oncology
hydrophobic groove is called the BH3-binding domain. In general
terms, these domains define the functionality of three groups within
the Bcl-2 family: two groups of either proapoptotic or antiapoptotic
effector molecules bearing multiple BH domains and one group of
facilitator or potentiator molecules bearing only the BH3 domain
(BH3-only proteins;Fig 2). The proapoptotic effectors Bax and Bak
form oligomeric pores in the mitochondrial membrane that allow
egress of apoptotic signaling molecules, whereas the antiapoptotic
effectors Bcl-2, Bcl-xL, Mcl-1, and Bfl-1/A1 bind to Bax or Bak and
inhibit functional oligomerization. The proapoptotic BH3-only mol-
ecules may interact with the effector molecules to promote pore for-
mation either by competitively inhibiting Bcl-2/Bcl-xL/Mcl-1, binding
to Bax/Bak, or by directly promoting Bax/Bak oligomerization.6,8
There are a number of models, variations on the above theme, pro-
posed to explain the interaction of these proteins and how, or even
whether, they induce apoptosis signaling via the mitochondria. Ex-
actly how this happens is unclear in real cellular models at this time
(see Skommer et al6 for further discussion).
BCL-2: ROLE IN ANGIOGENESIS AND TUMOR STATUS
Angiogenesis is the mechanism by which blood vessels form from
existing vasculature.9 It is fundamental to normal growth and devel-
opment and as part of the physiologic response to wounding. Hyper-
plastic cell growth both encourages and requires formation of new
blood vessels, as evidenced by the generally high vascularity of tumors.
Indeed, beyond 1- to 2-mm size, tumors cannot sustain expansion
without induction of angiogenesis. Simple diffusion of nutrients is
clearly insufficient to maintain tumor growth.10 Three of the primary
activators of angiogenesis are vascular endothelial growth factor
(VEGF), CXCL1 (growth-related oncogene, GRO-alpha), and CXCL8
(interleukin-8), promoting endothelial cell survival and proliferation.11,12
The involvement of Bcl-2 as a proangiogenic signaling molecule
is only now becoming clearer for both tumor cells and vascular endo-
thelial cells (Fig 1). Indeed it has long been recognized that both Bcl-2
and Bfl-1/A1 are mediators of protection for endothelial cells,13 al-
though Bfl-1/A1 seems to perform a rapid, and more transient, func-
tion than Bcl-2, potentially related to inflammatory response.13,14
Although modulation of Bcl-2 in endothelial cells has been shown to
affect angiogenesis in vitro and in vivo (discussed further in this
paragraph and in Bcl-2 Inhibitors as Antiangiogenic Agents), little is
known about the molecular mechanisms involved. Stimulation of the
VEGF pathway results in increased expression of Bcl-2 in both tumor
cells15 and endothelial cells.13,16,17 Bcl-2 upregulation in turn increases
VEGF expression in endothelial cells and in tumor cells of various
lineages.18-20 Notably, Bcl-2 upregulation induces expression of the
proangiogenic chemokines CXCL1 and CXCL8 through activation of
the NF-kB signaling pathway in endothelial cells.16,21 It has recently
been shown in human tumor biopsies that Bcl-2 is massively upregu-
lated in head and neck squamous cell carcinoma–associated endothe-
lial cells compared with endothelial cells in normal oral mucosa.20 In
this study, it was also demonstrated in vivo that factors secreted by
endothelial cells, in response to modulation of Bcl-2 expression levels
in neovascular endothelial cells, have a direct effect on tumor cell
NFKβ








































Fig 1. Role of Bcl-2 in tumor cell and
endothelial cell apoptosis and survival. Di-
agram depicts the involvement of Bcl-2 in
tumor cell and endothelial cell function, as
well as in the regulation of cross-talks
between the two cell types. Bcl-2 is a
pivotal checkpoint in the apoptotic path-
way, inhibiting the proapoptotic actions of
Bax and Bak. Both Bcl-2 expression and
hypoxia may result in vascular endothelial
growth factor (VEGF) production, which is
secreted by the tumor cell. Endogenous
VEGF can bind to VEGF receptor 1
(VEGFR1) on tumor cells sending a prosur-
vival signal, upregulating Bcl-2 production,
or can also bind to VEGFR2 on endothelial
cells, promoting cell survival and stimulat-
























Fig 2. Bcl-2 family of proteins. This is a nonexhaustive list of the Bcl-2 family of
proteins, showing the conserved Bcl-2 homology (BH) domains, the transmem-
brane domains (TM), and the three primary classes of molecular activity. Bcl-2,
Bcl-xL, Mcl-1, and Bcl-w represent the major molecules in the antiapoptotic class
of effector molecules. Bax, Bak, and Bok represent the proapoptotic effector
molecules, lacking BH4 domain. The proapoptotic facilitator molecules bear only
the BH3 domain and may lack the transmembrane domain. Sizes are represen-
tative and drawn to approximate scale relative to molecular weight.
Small-Molecule Inhibitors of Bcl-2 in Cancer Therapy
www.jco.org © 2008 by American Society of Clinical Oncology 4181
growth.20 Additionally, the authors showed expression of VEGF to be
significantly attenuated in vitro by small inhibitory RNA directed
against Bcl-2, in both Bcl-2 overexpressing and control endothelial
cells.20 It is clear that disruption of the Bcl-2 pathway may be expected
to affect angiogenesis, both directly by inhibiting function of endothe-
lial cells and, as many cancers display increased Bcl-2 expression, by
concomitant reduction in levels of endothelial-stimulating factors,
such as VEGF, CXCL1, and CXCL8 (Fig 1). Recently, endothelium-
targeted Bcl-2 overexpression was shown to induce disruption of the
blood vessel architecture and induce embryonic lethality in transgenic
mice.22 This effect was limited to the microvasculature and related to a
reduction in endothelial apoptosis, thus directly linking Bcl-2 levels
during development to angiogenic function.22
It should be noted that the clinical picture of Bcl-2 involvement
in cancer progression or patient survival is unclear, with different
studies finding varying degrees of correlation between Bcl-2 expres-
sion and disease severity or prognosis, both within and between
cancer types.23,24 Moreover, there is no clear reason why Bcl-2
expression, as a negative or positive prognostic factor, should bear
any relation to whether Bcl-2 is considered as a beneficial therapeutic
target. One example of this dichotomy is that of small-cell lung cancer
(SCLC) or non–small-cell lung cancer (NSCLC). Meta-analysis of the
data from 28 clinical studies indicated that Bcl-2 expression was asso-
ciated with good prognosis in NSCLC but had no correlation with
disease state in SCLC.25 Furthermore, some individual studies have
indeed shown correlation between Bcl-2 or Bcl-xL expression and
poor disease prognosis in NSCLC.26,27 However, in vitro and in vivo
studies consistently correlate increased Bcl-2 or Bcl-xL expression with
tumor aggression and tumor cell line resistance to chemotherapeutic
drugs.28-30 They have further shown regression and reversal of drug
resistance, by treatment with Bcl-2 family inhibitors, in SCLC tumors
and others.29,30
The disparity between tumor expression and therapeutic poten-
tial may result from varying methods of analysis, but may also be
explained at the cellular level. This is illustrated by two studies. In the
first, an acute lymphoblastic leukemia cell line treated with VEGF
expressed a phosphorylated form of Bcl-2, and apoptosis was re-
duced.31,32 The expression of nonphosphorylatable Bcl-2 in these cells
prevented this antiapoptotic effect. In contrast, the same authors32
also showed that VEGF-induced phosphorylation of Bcl-2 did not
protect chronic lymphoblastic leukemia cells under similar condi-
tions. Expression levels and post-translational modification of other
pro- or antiapoptotic proteins, in particular the BH3-only proteins,
may also account for the apparent differences.33-35 Furthermore, in-
activation of Bcl-xL by de-amidation occurs in response to common
chemotherapeutic drugs, such as cisplatin.36 With this number of
variables, it is clear that simply looking at the expression level of Bcl-2
alone in a tumor is insufficient to predict the benefits of anti–Bcl-2
therapy. Profiling the expression of many specific markers within a
tumor may provide a better indication for the suitability of therapies
targeting individual pathways, but this analysis is not routinely per-
formed. Accordingly, quantifiable RNA analysis of gene expression
and antibody arrays or Western blot analysis of proteins could usefully
supplement immunohistochemical data from tumor biopsies in fu-
ture studies. Thus, at this stage, it is difficult to predict which cancers
would benefit most from treatment with Bcl-2 inhibitors and in com-
bination with which conventional therapies.
BCL-2 INHIBITORS AS ANTITUMOR AGENTS
Both internal signaling and external stimuli may alter the complex
balance toward apoptosis by activation of the proapoptotic BH3-only
molecules and subsequent inactivation of Bcl-2/Bcl-xL, thus tipping
the balance in favor of apoptosis. Much research has been carried out
attempting to exploit the BH3-binding permissive network toward
development of Bcl-2/Bcl-xL inhibitors that result in activation of Bax
and Bak. A number of genetic and pharmacologic approaches have
been used to this end. Targeting Bcl-2 family RNA has shown positive
results, and oblimersen (Genasense; G3139; Genta Inc, Berkeley
Heights, NJ), an anti–Bcl-2 antisense oligonucleotide, has reached
phase III clinical trials in combination therapy.37 Peptide-based drugs
have also been shown both to attenuate Bcl-2 activity38 and to activate
Bax.8 However, nonpeptidic small-molecule inhibitors of signaling
pathways are likely to remain developmental drugs of choice for the
short to medium term, particularly because of the inherent low anti-
genicity of nonprotein organic compounds. In addition, the ease and
plasticity of molecular modification allows ready tailoring of putative
drugs. This last allows manipulation of compounds to aid route-
specific delivery, increase bioavailability, increase target affinity, and,
hopefully, to reduce patient drug load. This is a relatively new area for
Bcl-2 inhibitors, and currently few compounds have been under de-
velopmental and clinical study since the start of the decade. Only
within the last 6 to 12 months have publications appeared on a newer,
larger group of compounds. The established compounds with avail-
able experimental data are discussed next in the context of cancer and
angiogenesis. In this review, these compounds have been categorized
as derived from natural sources (see “From Nature”) or compounds
that were designed in laboratories (see “From Desktop to Benchtop
to Bedside”).
From Nature
The first drugs to be examined for therapeutic potential in many
diseases are generally pre-existing compounds that may be in use for
ostensibly unrelated purposes. Even where they have been examined
for anticancer activity, their molecular targets are rarely known in
advance. This has certainly been true for Bcl-2 inhibitors. The health
benefits of green and black tea polyphenols, in particular catechins
and theaflavins, have been touted as almost the nearest equivalent
to natural cure-alls. Indeed they do seem to have remarkably broad
therapeutic properties according to the literature39-42 and are com-
monly listed as small-molecule Bcl-2 inhibitors in cancer-related pub-
lications. Work from the Burnham Institute for Medical Research,
using nuclear magnetic resonance structural data and binding dis-
placement studies, provided clear evidence of binding between green
or black tea polyphenols and Bcl-2 and Bcl-xL.
43,44 They also readily
induce apoptosis in tumor cells in vitro and in vivo.45-48 However,
tea polyphenols, and in particular the major active component
epigallocatechin-3-gallate (EGCG; Fig 3F, Table 1), have been shown
to act as highly specific ligands for a variety of cellular pathways other
than those of Bcl-2. These include inhibition of platelet-derived
growth factor receptor ligand binding,71 tyrosine phosphorylation of
the Her/Neu epidermal growth factor receptor,72 and signaling by the
metastasis-associated 67-kDa laminin receptor.73 Expression of this
last receptor conferred specific responsiveness on cancer cells to the
growth inhibitory effects of EGCG and bound EGCG with a Kd of 39.9
nmol/L.73 In addition to these extracellular targets, tea polyphenols
Zeitlin, Zeitlin, and Nör
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(EGCG in particular) have been shown to bind to, or directly affect,
the pathways of a number of signaling molecules, including cyclo-
oxygenase and retinoblastoma protein.74,75 These all may have equal
claim, alongside Bcl-2, to be the cancer cell inhibitory targets for this
class of compounds. Therefore, although tea polyphenols remain an
exciting area for investigation as active antitumor-cell drugs, it is
difficult to accurately describe them as primarily acting via the Bcl-
2 pathway.
The other major natural derivative in this class, gossypol, was
isolated from the cotton plant and has been well studied as a contra-
ceptive for human males.76 However, gossypol, and in particular the
()-gossypol enantiomer (AT-101; Ascenta Therapeutics Inc,
Malvern, PA; Fig 3C, Table 1), was found to bind to Bcl-2 and Bcl-xL
through fluorescence-based ligand competition assay and nuclear
magnetic resonance binding analysis.49 In contrast with tea polyphe-
nols, there is a preponderance of evidence to suggest that the Bcl-2
family is a specific target of gossypol for induction of apoptosis. Al-
though gossypol does bind to other molecules, calcineurin,
glutathione-s-transferase, and lactate dehydrogenase with good affin-



















































































Fig 3. Small-molecule inhibitors of Bcl-2
family proteins. Chemical structures of
the various small-molecule inhibitors of
Bcl-2 discussed in this review. EGCG,
epigallocatechin-3-gallate.





Binding Coefficients† Reported Range In Vivo
Studies (first author)Bcl-2 Bcl-xL Mcl-1 Therapeutic
MTD
(mg/kg qd)
Gossypol 2.2-13.2 0.28-50 0.4-3.03 1.75 5-30 mg/kg 3  40 Kitada,49 Zhang,50 Mohammad,51 Wolter,52 Bauer,29
Xu,53 Zeitlin,55 Van Poznak57
HA14-1 5-20 0.9-100 NA NA 400 nmol (approximately
136 g)/mouse
NA van Delft,7 Wang,54 Lickliter,56 Chen,58 Manero59
TW-37 0.2-0.29 0.12-0.7 1.11 0.26 3-30 mg/kg qd 3  40 Wang,60 Mohammad,61 Zeitlin,55 Verhaegen62
GX15-070 1.7 1.11‡ 4.69‡ 2.9‡ 0.25-3 mg/kg/d iv NA Zhai,43 Campàs,63 Nguyen64
ABT-737 0.13-5 0.12 0.064  20 20-100 mg/kg/ip qd NA van Delft,7 Oltersdorf,30 Konopleva,65 Zhai43
EGCG 20-65 0.45 0.59 0.92 1.5 mg/d ip NA Yang,45 Pan,46 Navarro-Perán,47 Jung48
Antimycin A and
derivatives
0.37-0.7 0.82-100 2.7 2.51 2 mg/kg ip NA van Delft,7 Zhai,43 Tzung,66 Manion,67 Kim,68 Cao,69
Guichard70
NOTE. Values are representative ranges of activities for drugs in a variety of cells and conditions. Lack of consistent and comparable studies between various
compounds makes more exact reporting of values difficult to interpret.
Abbreviations: IC50, half maximal inhibitory concentration; MTD, maximum-tolerated dose; qd, each day; NA, not available at time of writing; iv, intravenously; ip,
intraperitoneally.
Refers to reported IC50, half maximal effective concentration (EC50), or median lethal dose (LD50).
†Determined using varying competitive binding assays.
‡Data for GX15, derivative of clinically tested GX15-070.
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induction of apoptosis.77-79 Higher Bcl-2 expression levels in tumor
cell lines have been correlated with increased apoptotic efficacy of
gossypol.80,81 Notably, in addition to a direct Bcl-2 inhibitory action,
gossypol modulates Bcl-2 family balance by downregulating the anti-
apoptotic members of the Bcl-2 family and upregulating the proapop-
totic members in a concentration and cell-line specific manner.50,82,83
As a single agent, the ()-gossypol enantiomer has shown encourag-
ing efficacy in vivo in a head and neck cancer model.52 ()-Gossypol
has also been shown to overcome cisplatin resistance in vitro in a head
and neck cancer line.29 Two recent in vivo studies have reported a
cooperative effect for administration of ()-gossypol in conjunc-
tion either with chemotherapy (cyclophosphamide, doxorubicin,
vincristine, and prednisolone regimen) or radiotherapy.51,53 A sig-
nificant decrease in xenograft tumor volume (cells from a patient with
clinically resistant diffuse large-cell lymphoma) was observed when
animals were treated with ()-gossypol/ cyclophosphamide, doxoru-
bicin, vincristine, and prednisolone chemotherapy as compared with
either individual treatment alone.
Mixed results were seen for racemic gossypol in phase I/II trials,
but no severe toxicity was observed, except during determination of
maximum-tolerated doses, where severe emesis was the dose-
limiting toxicity.57,84-86 Currently, phase I/II clinical trials are un-
derway for ()-gossypol (AT-101) in single-agent treatment of
relapsed B-cell malignancy. The compound is also being assessed in
combination therapy with docetaxel and prednisone for hormone-
refractory prostate cancer and also with an anti-CD20 antibody, rit-
uximab, for chronic lymphocytic leukemia (see clinical trial listing at
www.cancer.gov). Two further clinical trials have been approved for
relapsed/refractory SCLC and newly diagnosed glioblastoma multi-
forme (www.cancer.gov).
Also under development are derivatives of Antimycin A, isolated
from Streptomyces. Antimycin A (Fig 3G, Table 1) is an antifungal
compound and a mitochondrial poison that targets complex III of the
respiratory chain and that was shown to bind to the BH3 binding
domain of Bcl-2/Bcl-xL.
43,66,67 It is highly toxic in mouse models, with
a single median lethal dose of 1 mg/kg.66,68,87 Although a large body of
literature can be found for the parent molecule, considerably less work
has been published about the newer, less toxic derivatives, in particu-
lar, 2-methoxyantimycin.66,69,87,88 2-Methoxyantimycin has been
shown to function cooperatively with paclitaxel and docetaxel to in-
duce apoptosis, whereas the parental compound, Antimycin A, dis-
played synergy with the topoisomerase inhibitor SN-38 in inhibiting
cell growth in a human colon cancer line.70,87 If the less toxic antimy-
cin analogs can retain activity displayed in the few available studies,
they may prove to be a particularly interesting drug series.
From Desktop and Benchtop to Bedside
Inspired by the potential of natural Bcl-2 inhibitors, several re-
search groups have developed specific inhibitors of Bcl-2. Primarily,
various forms of in silico and in vitro screening of combinatorial
libraries, for best-fit compounds, have resulted in Bcl-2 inhibitors of
varying capacity and high affinity for one or more of the Bcl-2 family of
proteins. HA14-1 (Fig 3D, Table 1) was the first Bcl-2–binding ligand
to be discovered using these computer-based screening strategies us-
ing the predicted structure of Bcl-2.54
Both synergistic and additive effects of HA14-1, with other chem-
otherapeutic compounds, contributed to reversal of drug resistance in
vitro in a broad variety of cell lines and treatment regimens.56,58,89-92
Notably, the order of treatment in a combination regimen made a
profound difference in the final effect. HA14-1 acts as a radiosensitizer
on LNCaP and PC3 prostate cancer cell lines with or without overex-
pression of Bcl-2. Synergy was only seen in the PC3 cells when HA14-1
was administered after exposure to gamma radiation, and not in
the reverse order.91 In glioblastoma cells, a 1-hour pretreatment with
HA14-1 sensitized the cells to radiation in a Bcl-2, but not Bcl-xL,
dependent manner.59 Skommer et al90 found synergy between
HA14-1 and dexamethasone or doxorubicin, but not vincristine, in
inhibiting B-cell lymphoma tumor cell proliferation. They observed
that for HA14-1 and doxorubicin, synergistic inhibition was seen only
when the Bcl-2 inhibitor was administered 24 hours before the con-
ventional chemotherapeutic drugs, and antagonism was seen if they
were administered simultaneously. In combination with the cyclin-
dependent kinase (CDK) inhibitor flavopiridol, HA14-1 displays a
similar synergy, but in this instance, only when the Bcl-2 inhibitor is
administered after the CDK inhibitor.93 It is noteworthy that the
precise order of administration of HA14-1 in radiation, doxorubicin,
or flavopiridol studies was important for enhancement of the inhibi-
tory effect of HA14-1. Although not reported for all the Bcl-2 small-
molecule inhibitors, most classes of drugs display administration
order preferences for optimal cooperation with other therapeutic
agents. The varying results, described above, for HA14-1 in combina-
tion therapy with radiation or chemotherapeutics may be due to
tumor-specific differences in target expression (Bcl-2/Bcl-xL/Mcl-1)
or modulation of those proteins by whichever therapy is adminis-
tered first.
Other small-molecule inhibitors of Bcl-2 began to appear after
HA14-1, in particular TW-37 (TW37) and ABT-737. Both TW-37
and ABT-737 improve on HA14-1 in efficacy, having nanomolar
affinities for Bcl-2. However, only TW-37 has nanomolar to low
micromolar affinities for all of the major antiapoptotic members of
the Bcl-2 family of proteins. TW-37 (Fig 3B, Table 1) represents a new
class of pan-Bcl-2 protein family inhibitor. It is a BH3 mimetic devel-
oped by rational structural design using a computer-based modeling
strategy.60,61 Apoptosis was shown to be the primary mechanism for
the growth-inhibitory properties of TW-37 in the prostate cancer cell
line PC3.60 TW-37 has also been shown to effectively inhibit growth
of Kaposi’s sarcoma (SLK), breast cancer (MCF-7), and prostate
cancer (LnCap) cell lines without inhibitory effects on human
dermal fibroblasts.55
Melanoma is particularly resistant to conventional chemothera-
pies.94 TW-37 was found to be effective against melanoma-derived
tumors when jointly administered with the mitogen-activated protein
kinase kinase (MEK) inhibitors U0126 or CL-1040 and, to a lesser
extent, as single agent both in vivo and in vitro.62 The rationale for
coadministration was that some melanomas respond poorly to
mitogen-activated protein kinase inhibition, possibly through ERK-
mediated upregulation of the antiapoptotic Bcl-2 family of proteins.
Using lentiviral-driven inhibitory RNA, the Soengas group produced
a series of isogenic melanoma cell lines deficient in specific molecules
of the apoptosis pathway. They identified Bcl-2, Mcl-1, and Bcl-xL as
integral components of resistance to MEK inhibition.62 They also
showed synergistic inhibition of melanoma cell growth by TW-37 and
the MEK inhibitors in vitro. Notably, in vivo coadministration signif-
icantly inhibited xenografted melanoma tumor growth when com-
pared with either agent alone.62
Zeitlin, Zeitlin, and Nör
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In an initial study by Oltersdorf et al,30 ABT-737 (Fig 3E, Table
1) was shown to bind Bcl-2, Bcl-xL, and Bcl-w with high affinity
(Ki  1 nmol/L), but to have extremely low affinity for Mcl-1,
Bcl-b, and A1. Indeed, the low affinity for Mcl-1 has defined part of
the research into this compound, as the drug efficacy is greatly
attenuated in the presence of that protein. ABT-737 was effective in
delaying growth of tumors overexpressing Bcl-2. In contrast, tu-
mors transduced with vectors inducing Mcl-1 overexpression were
highly refractory to the drug.95 Additionally, ABT-737 induced
thrombocytopenia in mice in a transient and reversible manner
but was nontoxic to hematopoietic progenitor cells, including
megakaryocytes.65,96,97 This was shown to occur via direct inhibi-
tion of platelet Bcl-xL by ABT-737, preventing binding of Bcl-xL to
Bak and inducing Bak-mediated platelet apoptosis.97 Recently,
Chen et al98 have shown that selective downregulation of Mcl-1,
either by CDK inhibitors such as roscovitine or by gene silencing,
synergistically increases the sensitivity of human leukemia cells to
ABT-737–induced apoptosis.
Given these issues, it is notable that ABT-737 is a highly active
drug in several models. It has shown antitumor efficacy, as a single
agent administered intraperitoneally, in two models of lung cancer
using cell lines with known sensitivity to the compound and also in
models of leukemia.30,65 In chronic myelogenous leukemia, the Bcr/
Abl pathway promotes leukemogenesis, but the Bcr/Abl inhibitor
(imatinib; Gleevec, Novartis Pharmaceuticals Corp, East Hanover,
NJ) induces apoptosis in affected cells via a Bcl-2/Bcl-xL–mediated path-
way.99 Coadministration of ABT-737 and imatinib to Bim/Bad double
knockout Bcr/Abl-positive cells enhanced apoptosis as compared with
either drug alone.100 Thus ABT-737 seems to compensate for the loss of
the BH3-only proteins Bim or Bad. It remains to be seen whether ABT-
737 moves on to clinical trial, although a structurally related, orally avail-
able analog, ABT-263, is indeed entering phase I/II clinical trials for
lymphocytic leukemia and SCLC101 (www.cancer.gov).
Another small-molecule inhibitor of all the major Bcl-2 anti-
apoptotic family proteins, GX15-070 (Obatoclax; Fig 3A; Table 1),
was developed by Gemin X Biotechnologies Inc. (Montreal, Que-
bec, Canada). Although it was the first of the specifically designed
Bcl-2 small-molecule inhibitor drugs to be approved in the United
States for four clinical trials (www.cancer.gov) and has been under
patent since 2002, little has yet been published on this compound.
In one study by Campas et al,63 GX15-070 displayed a mean half
maximal effective concentration of 1.7  0.1 mol/L in isolated
cell lines, ranging over a 48-hour period. However, this calcula-
tion of activity excluded two lines of 11, which were considered
resistant to GX15-070. Therefore, reliable determination of the
activity of this drug within this class of tumors must await other
confirmatory studies at this time. Additive effects were reported in
combination with fludarabine and chlorambucil administered
with 0.5 mol/L of GX15-070. However, synergy was observed for
GX15-070 administered with the proteasome inhibitor, bort-
ezomib, and the order of administration was not reported to alter
synergistic efficacy.64,102 In three mantle-cell lymphoma lines stud-
ied, apoptotic concentrations of GX15-070 were able to inhibit
binding of immunoprecipitated Mcl-1 and Bcl-xL to Bak, resulting
in mitochondrial depolarization and caspase-3 activation. The
synergistic effects of GX15-070 with bortezomib on cytotoxicity in
tumor cells were attributed in large part to inhibition of the Mcl-
1/Bak interaction. Interestingly, they were also attributed to the in-
hibitory effects of GX15-070 on Mcl-1 expression, which may have
countered the strong upregulation of Mcl-1 expression induced by
bortezomib treatment.64,102
BCL-2 INHIBITORS AS ANTIANGIOGENIC AGENTS
As discussed previously, Bcl-2 is intimately involved with angio-
genesis through modulation of both endothelial and tumor cell
signaling. Additionally, Bcl-2 inhibitors may directly induce apo-
ptosis in angiogenically active endothelial cells in vitro, in similar
fashion to their effect on tumor cells, and endothelial cell-specific
apoptosis can disrupt neovascularization in vivo.55,103 Therefore,
Bcl-2 and its related signaling network becomes a logical target for
antiangiogenic cancer therapy (Fig 1). There is an emerging body
of literature on the in vivo antiangiogenic effect of inhibition of the
Bcl-2 family of proteins. Notably, most of what is available has been
presented as unquantified immunohistochemical data. However,
direct effects of Bcl-2 inhibition have been quantified in at least one
study, which reported a significant reduction in microvessel vessel
density after TW-37 treatment in a humanized in vivo model of
angiogenesis.55 Of other studies, the antiangiogenic effects of
EGCG have been demonstrated, including a significant reduction
in microvessel density within xenografted ovarian cancer cell tu-
mors and colon cancer tumors.48,104 However, as discussed previ-
ously, it may be pre-emptive to use EGCG as an example of an
inhibitor inducing apoptosis solely through effects on Bcl-2. ()-
Gossypol has been shown to have potential antiangiogenic efficacy
in vivo when administered in conjunction with radiotherapy, al-
though without quantification of the reported changes in vessel
density.53 In total, these reports suggest that Bcl-2– dependent
vasculature may indeed be targeted, in vivo, by small-molecule
inhibitors of Bcl-2. Broadening the scope of literature search, two
groups have published studies using antisense oligonucleotides to
inhibit Bcl-2 expression in melanoma or prostate cancer cells
transfected with Bcl-2.105,106 Anai et al106 observed a reduction in
microvessel density when the same cells were implanted as xeno-
grafts. Together, the work published to date suggests that Bcl-2
inhibition, whether by pharmacologic or genetic means, may po-
tentially inhibit angiogenesis toward a therapeutic end.
SUMMARY AND IMPLICATIONS
There is an expanding industry devoted toward inhibiting various
components of the Bcl-2 pathway using designer small-molecule
drugs (mw approximately 400 to 800). These newly developed or
identified compounds not only provide us with novel therapeutic
approaches to cancer treatment but also deliver new tools for
the analysis of the many functions of the Bcl-2 family of proteins.
With our knowledge of the Bcl-2 family expanding rapidly, this
specific avenue of pharmaceutical development is unlikely to
slow down in the near future. It is strengthened by the proven
therapeutic efficacy of both older and more recent pharmacologic
agents in vivo, particularly ()-gossypol and ABT-737, and the
utility of the same compounds for dissection of apoptotic and
angiogenic pathways.
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Possibly the most useful similarities shared by these drugs are
their low overall toxicities in comparison with conventional cancer
therapeutics and, often, their ability to synergize with those thera-
peutics to inhibit tumor cell survival. Although Bcl-2 small-
molecule inhibitors are not magic bullets, they do provide a new
weapon for the existing anticancer arsenal. Perhaps in sniping at
new sites of blood vessel growth around metastatic sites, or used in
barrage with the combined force of traditional chemotherapeutics
or radiotherapy, they might prove to be efficient and safe for
patients with cancer. However applied, small-molecule inhibitors
of Bcl-2 have marked potential for cancer research and treatment.
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Glossary Terms
Bcl-2: First discovered as a translocated locus [t(14;22)] in
B-cell leukemias, bcl-2 is an antiapoptotic protein that protects
cells from programmed cell death by preventing the activation of
proapoptotic caspase proteins.
Bcl-xL: An antiapoptotic member of the Bcl-2 family of proteins,
Bcl-x is a homolog of Bcl-2. Depending on splicing, Bcl-x may be
present either as the short (Bcl-xS) or the long (Bcl-xL) form. Of
these, Bcl-xL has antiapoptotic properties similar to Bcl-2.
VEGF (vascular endothelial growth factor): VEGF is a
cytokine that mediates numerous functions of endothelial cells, in-
cluding proliferation, migration, invasion, survival, and permeabil-
ity. VEGF is also known as vascular permeability factor. VEGF
naturally occurs as a glycoprotein and is critical for angiogenesis.
Many tumors overexpress VEGF, which correlates to poor progno-
sis. VEGF-A, -B, -C, -D, and -E are members of the larger family of
VEGF-related proteins.
Angiogenesis: The process involved in the generation of new
blood vessels. While this is a normal process that naturally occurs
and is controlled by “on” and “off ” switches, blocking tumor angio-
genesis (antiangiogenesis) disrupts the blood supply to tumors,
thereby preventing tumor growth.
BH3-binding domain: Hydrophobic groove present in Bcl-2, and
some related proteins, that acts as a binding target for the BH3 domain of
other proteins. The BH3-binding domain is the primary target for certain
small molecule inhibitor drugs that prevent BH3-domain binding and in-
duce apoptosis.
TW-37 (TW37): Small molecule inhibitor of Bcl-2 and Bcl-2 family of
anti-apoptotic proteins, induces apoptosis in sensitive cells. TW-37 is an
example of a new group of molecules designed to inhibit Bcl-2 and related
proteins by targeting their BH3-binding domain. TW-37 is currently in
pre-clinical trials.
()-Gossypol: Negative enantiomer of a polyphenolic molecule derived
from the cotton plant. Having male contraceptive properties, it is a natural
compound known to inhibit Bcl-2 and Bcl-xL function via targeting their
BH3-binding domain. ()-Gossypol is currently entering clinical trial for
cancer treatment.
Oblimersen (Genasense): Antisense oligonucleotide inhibiting Bcl-2
mRNA translation and therefore protein production. This is an example of
a genetic inhibitor of Bcl-2 currently in clinical trial.
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